147 related articles for article (PubMed ID: 38556760)
21. Inhibition of Mertk Signaling Enhances Bone Healing after Tooth Extraction.
Decker AM; Matsumoto M; Decker JT; Roh A; Inohara N; Sugai J; Martin K; Taichman R; Kaigler D; Shea LD; Núñez G
J Dent Res; 2023 Sep; 102(10):1131-1140. PubMed ID: 37350025
[TBL] [Abstract][Full Text] [Related]
22. Discovery of 5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine derivatives as novel selective Axl inhibitors.
Inoue S; Yamane Y; Tsukamoto S; Murai N; Azuma H; Nagao S; Nishibata K; Fukushima S; Ichikawa K; Nakagawa T; Hata Sugi N; Ito D; Kato Y; Goto A; Kakiuchi D; Ueno T; Matsui J; Matsushima T
Bioorg Med Chem Lett; 2021 Sep; 48():128247. PubMed ID: 34271070
[TBL] [Abstract][Full Text] [Related]
23.
Saito T; Itoh M; Tohda S
Anticancer Res; 2022 Apr; 42(4):1757-1761. PubMed ID: 35346994
[TBL] [Abstract][Full Text] [Related]
24. Overexpression of MERTK receptor tyrosine kinase in epithelial cancer cells drives efferocytosis in a gain-of-function capacity.
Nguyen KQ; Tsou WI; Calarese DA; Kimani SG; Singh S; Hsieh S; Liu Y; Lu B; Wu Y; Garforth SJ; Almo SC; Kotenko SV; Birge RB
J Biol Chem; 2014 Sep; 289(37):25737-49. PubMed ID: 25074939
[TBL] [Abstract][Full Text] [Related]
25. AXL Inhibition Induces DNA Damage and Replication Stress in Non-Small Cell Lung Cancer Cells and Promotes Sensitivity to ATR Inhibitors.
Ramkumar K; Stewart CA; Cargill KR; Della Corte CM; Wang Q; Shen L; Diao L; Cardnell RJ; Peng DH; Rodriguez BL; Fan YH; Heymach JV; Wang J; Gay CM; Gibbons DL; Byers LA
Mol Cancer Res; 2021 Mar; 19(3):485-497. PubMed ID: 33172976
[TBL] [Abstract][Full Text] [Related]
26. A Functional Role of GAS6/TAM in Nonalcoholic Steatohepatitis Progression Implicates AXL as Therapeutic Target.
Tutusaus A; de Gregorio E; Cucarull B; Cristóbal H; Aresté C; Graupera I; Coll M; Colell A; Gausdal G; Lorens JB; García de Frutos P; Morales A; Marí M
Cell Mol Gastroenterol Hepatol; 2020; 9(3):349-368. PubMed ID: 31689560
[TBL] [Abstract][Full Text] [Related]
27. MERTK controls melanoma cell migration and survival and differentially regulates cell behavior relative to AXL.
Tworkoski KA; Platt JT; Bacchiocchi A; Bosenberg M; Boggon TJ; Stern DF
Pigment Cell Melanoma Res; 2013 Jul; 26(4):527-41. PubMed ID: 23617806
[TBL] [Abstract][Full Text] [Related]
28. Dissecting the Role of AXL in Cancer Immune Escape and Resistance to Immune Checkpoint Inhibition.
Engelsen AST; Lotsberg ML; Abou Khouzam R; Thiery JP; Lorens JB; Chouaib S; Terry S
Front Immunol; 2022; 13():869676. PubMed ID: 35572601
[TBL] [Abstract][Full Text] [Related]
29. Macrophage AXL receptor tyrosine kinase inflames the heart after reperfused myocardial infarction.
DeBerge M; Glinton K; Subramanian M; Wilsbacher LD; Rothlin CV; Tabas I; Thorp EB
J Clin Invest; 2021 Mar; 131(6):. PubMed ID: 33529176
[TBL] [Abstract][Full Text] [Related]
30. Cell softening in malignant progression of human lung cancer cells by activation of receptor tyrosine kinase AXL.
Iida K; Sakai R; Yokoyama S; Kobayashi N; Togo S; Yoshikawa HY; Rawangkan A; Namiki K; Suganuma M
Sci Rep; 2017 Dec; 7(1):17770. PubMed ID: 29259259
[TBL] [Abstract][Full Text] [Related]
31. [Tyro3 and CDK9 as biomarkers for drug resistance to breast cancer anti-PD-1 therapies].
Zhang JF; Liu T
Zhonghua Zhong Liu Za Zhi; 2023 Aug; 45(8):651-656. PubMed ID: 37580269
[No Abstract] [Full Text] [Related]
32. TAM receptor tyrosine kinase function and the immunopathology of liver disease.
Mukherjee SK; Wilhelm A; Antoniades CG
Am J Physiol Gastrointest Liver Physiol; 2016 Jun; 310(11):G899-905. PubMed ID: 26867565
[TBL] [Abstract][Full Text] [Related]
33. TAM family kinases as therapeutic targets at the interface of cancer and immunity.
DeRyckere D; Huelse JM; Earp HS; Graham DK
Nat Rev Clin Oncol; 2023 Nov; 20(11):755-779. PubMed ID: 37667010
[TBL] [Abstract][Full Text] [Related]
34. Phosphatidylserine Sensing by TAM Receptors Regulates AKT-Dependent Chemoresistance and PD-L1 Expression.
Kasikara C; Kumar S; Kimani S; Tsou WI; Geng K; Davra V; Sriram G; Devoe C; Nguyen KN; Antes A; Krantz A; Rymarczyk G; Wilczynski A; Empig C; Freimark B; Gray M; Schlunegger K; Hutchins J; Kotenko SV; Birge RB
Mol Cancer Res; 2017 Jun; 15(6):753-764. PubMed ID: 28184013
[TBL] [Abstract][Full Text] [Related]
35. A Potent and Selective Dual Inhibitor of AXL and MERTK Possesses Both Immunomodulatory and Tumor-Targeted Activity.
Rios-Doria J; Favata M; Lasky K; Feldman P; Lo Y; Yang G; Stevens C; Wen X; Sehra S; Katiyar K; Liu K; Wynn R; Harris JJ; Ye M; Spitz S; Wang X; He C; Li YL; Yao W; Covington M; Scherle P; Koblish H
Front Oncol; 2020; 10():598477. PubMed ID: 33425754
[TBL] [Abstract][Full Text] [Related]
36. Therapeutic targeting of the functionally elusive TAM receptor family.
Miao YR; Rankin EB; Giaccia AJ
Nat Rev Drug Discov; 2024 Mar; 23(3):201-217. PubMed ID: 38092952
[TBL] [Abstract][Full Text] [Related]
37. Antagonistic Coevolution of MER Tyrosine Kinase Expression and Function.
Evans AL; Blackburn JWD; Taruc K; Kipp A; Dirk BS; Hunt NR; Barr SD; Dikeakos JD; Heit B
Mol Biol Evol; 2017 Jul; 34(7):1613-1628. PubMed ID: 28369510
[TBL] [Abstract][Full Text] [Related]
38. MerTK inhibition is a novel therapeutic approach for glioblastoma multiforme.
Knubel KH; Pernu BM; Sufit A; Nelson S; Pierce AM; Keating AK
Oncotarget; 2014 Mar; 5(5):1338-51. PubMed ID: 24658326
[TBL] [Abstract][Full Text] [Related]
39. TAM receptor tyrosine kinases as emerging targets of innate immune checkpoint blockade for cancer therapy.
Akalu YT; Rothlin CV; Ghosh S
Immunol Rev; 2017 Mar; 276(1):165-177. PubMed ID: 28258690
[TBL] [Abstract][Full Text] [Related]
40. Immuno-oncological Efficacy of RXDX-106, a Novel TAM (TYRO3, AXL, MER) Family Small-Molecule Kinase Inhibitor.
Yokoyama Y; Lew ED; Seelige R; Tindall EA; Walsh C; Fagan PC; Lee JY; Nevarez R; Oh J; Tucker KD; Chen M; Diliberto A; Vaaler H; Smith KM; Albert A; Li G; Bui JD
Cancer Res; 2019 Apr; 79(8):1996-2008. PubMed ID: 30723115
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]